It has shown promising effects against CML, especially by targeting the BCR-ABL oncoprotein and several studies have explored how emodin works in CML cells, including those that are resistant to commonly used TKIs like imatinib. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.